| Literature DB >> 33923678 |
Charlotte Doidge1, Helen West2, Jasmeet Kaler1.
Abstract
Little data exist on the levels of antimicrobial resistance from bacteria isolated from British sheep and beef cattle. The aim of this study was to investigate antimicrobial resistance patterns on sheep and beef farms in England and Wales using multiple interpretation methods. Fecal samples (n = 350) from sheep and beef cattle were collected from 35 farms. Disk diffusion antimicrobial susceptibility testing against ten antimicrobials was carried out for 1115 (699 sheep, 416 beef) β-glucuronidase-positive Escherichia coli isolates. Susceptibility was interpreted using clinical breakpoints, which determine clinically resistant bacteria, and epidemiological and livestock-specific cut-off values, which determine microbiological-resistant bacteria (non-wild type). Using livestock-specific cut-off values, a high frequency of wild type for all ten antimicrobials was observed in isolates from sheep (90%) and beef cattle (85%). Cluster analysis was performed to identify patterns in antimicrobial resistance. Interpretation of susceptibility using livestock-specific cut-off values showed a cluster of isolates that were non-wild type to cefotaxime and amoxicillin/clavulanic acid, whereas clinical breakpoints did not. A multilevel logistic regression model determined that tetracycline use on the farm and soil copper concentration were significantly associated with tetracycline non-wild type isolates. The results suggest that using human clinical breakpoints could lead to both the under-reporting and over-reporting of antimicrobial resistance in sheep and beef cattle.Entities:
Keywords: Escherichia coli; antibiotic resistance; antimicrobial susceptibility testing; beef cattle; farms; normalised resistance interpretation; sheep; tetracyclines
Year: 2021 PMID: 33923678 PMCID: PMC8073771 DOI: 10.3390/antibiotics10040453
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Description of the farms where E. coli isolates were obtained including number of animals, region and number of isolates tested.
| Farm No. | Region | ||||
|---|---|---|---|---|---|
| 1 | West Midlands | 220 | 0 | 0 | 30 |
| 2 | West Midlands | 205 | 370 | 10 | 15 |
| 3 | West Midlands | 281 | 900 | 13 | 16 |
| 4 | Wales | 125 | 750 | 15 | 16 |
| 5 | South West England | 2240 | 0 | 0 | 32 |
| 6 | West Midlands | 172 | 350 | 25 | 15 |
| 7 | West Midlands | 342 | 0 | 0 | 32 |
| 8 | South West England | 500 | 0 | 0 | 36 |
| 9 | South West England | 218 | 1058 | 33 | 0 |
| 10 | Wales | 236 | 840 | 30 | 0 |
| 11 | Wales | 93 | 550 | 26 | 17 |
| 12 | Wales | 0 | 250 | 15 | 0 |
| 13 | Wales | 109 | 584 | 30 | 0 |
| 14 | South East England | 198 | 800 | 10 | 13 |
| 15 | Wales | 39 | 538 | 28 | 0 |
| 16 | Wales | 41 | 500 | 39 | 0 |
| 17 | Wales | 179 | 1850 | 15 | 15 |
| 18 | Wales | 600 | 800 | 15 | 15 |
| 19 | West Midlands | 107 | 0 | 0 | 30 |
| 20 | Wales | 161 | 582 | 30 | 0 |
| 21 | West Midlands | 0 | 300 | 39 | 0 |
| 22 | South West England | 49 | 480 | 29 | 0 |
| 23 | West Midlands | 157 | 520 | 40 | 0 |
| 24 | South West England | 64 | 560 | 30 | 0 |
| 25 | South West England | 209 | 600 | 29 | 0 |
| 26 | North East England | 200 | 500 | 25 | 15 |
| 27 | North West England | 420 | 0 | 0 | 30 |
| 28 | South West England | 241 | 0 | 0 | 30 |
| 29 | Wales | 0 | 300 | 28 | 0 |
| 30 | Wales | 145 | 466 | 27 | 15 |
| 31 | Wales | 23 | 360 | 39 | 0 |
| 32 | Wales | 564 | 1600 | 15 | 15 |
| 33 | West Midlands | 285 | 0 | 0 | 29 |
| 34 | West Midlands | 0 | 600 | 31 | 0 |
| 35 | Wales | 40 | 425 | 33 | 0 |
n = number.
Epidemiological cut-off values calculated using the NRI method compared with clinical breakpoints and ECOFF values.
| Antimicrobials | Disk Content | Clinical Breakpoint (S ≥ mm) | ECOFF WT ≥ mm | Sheep COWT WT ≥ mm | SD | Beef COWT WT ≥ mm | SD |
|---|---|---|---|---|---|---|---|
| Neomycin | 30 μg | - | - | 13 | 1.46 | 14 | 1.87 |
| Spectinomycin | 100 μg | - | - | 19 | 1.91 | 18 | 2.06 |
| Tetracycline | 30 μg | 15 | - | 25 | 2.25 | 26 | 2.17 |
| Amoxicillin/Clavulanic Acid | 20–10 µg | 19 | 16 | 15 | 3.15 | 15 * | 3.66 |
| Ciprofloxacin | 5 µg | 25 | 25 | 27 * | 3.72 | 32 | 2.42 |
| Ampicillin | 10 µg | 14 | 14 | 12 | 3.26 | 11 * | 3.61 |
| Sulfamethoxazole-Trimethoprim | 23.75–1.25 µg | 14 | 21 | 24 | 2.96 | 24 | 2.72 |
| Chloramphenicol | 30 µg | 17 | 17 | 18 * | 3.50 | 17 * | 3.65 |
| Cefotaxime | 5 µg | 20 | 21 | 26 | 2.26 | 26 | 3.04 |
| Imipenem | 10 µg | 22 | 24 | 27 | 2.82 | 27 * | 3.88 |
* SD > 3.34 mm and therefore COWT only a tentative estimate. S = susceptible, WT = wild type.
Prevalence of antimicrobial susceptible (S) and wild type (WT) E. coli isolated from sheep using clinical breakpoints, ECOFFs and the NRI method.
| Antimicrobial | Clinical Breakpoint (% S) | ECOFF (% WT) | Sheep COWT (% WT) | Kappa | |
|---|---|---|---|---|---|
| Neomycin | 699 | - | - | 99.6% | N/A |
| Spectinomycin | 699 | - | - | 95.9% | N/A |
| Tetracycline | 699 | 93.0% | - | 92.1% | 0.938 |
| Amoxicillin/Clavulanic Acid | 699 | 95.4% | 97.4% | 98.1% | 0.689 |
| Ciprofloxacin | 699 | 100% | 100% | 100% | N/A |
| Ampicillin | 699 | 94.7% | 94.7% | 95.1% | 0.971 |
| Sulfamethoxazole-Trimethoprim | 699 | 98.0% | 98.0% | 97.9% | 0.976 |
| Chloramphenicol | 699 | 99.3% | 99.3% | 99.3% | 1.000 |
| Cefotaxime | 699 | 99.7% | 99.1% | 98.7% | 0.585 |
| Imipenem | 699 | 100% | 100% | 100% | N/A |
Prevalence of antimicrobial susceptible (S) and wild type (WT) E. coli isolated from beef cattle using clinical breakpoints, ECOFFs and the NRI method.
| Antimicrobial | Clinical Breakpoint (% S) | ECOFF (% WT) | Beef COWT (% WT) | Kappa | |
|---|---|---|---|---|---|
| Neomycin | 416 | - | - | 100% | N/A |
| Spectinomycin | 416 | - | - | 99.0% | N/A |
| Tetracycline | 416 | 88.2% | - | 87.7% | 0.977 |
| Amoxicillin/Clavulanic Acid | 416 | 98.3% | 99.5% | 99.8% | 0.395 |
| Ciprofloxacin | 416 | 99.8% | 99.8% | 99.0% | 0.423 |
| Ampicillin | 416 | 97.8% | 97.8% | 97.8% | 1.000 |
| Sulfamethoxazole-Trimethoprim | 416 | 99.5% | 99.5% | 98.1% | 0.495 |
| Chloramphenicol | 416 | 97.6% | 97.6% | 97.6% | 1.000 |
| Cefotaxime | 416 | 99.5% | 99.3% | 99.0% | 0.776 |
| Imipenem | 416 | 100% | 100% | 100% | N/A |
Farm-level prevalence of antimicrobial susceptibility of all E. coli isolated from sheep and beef farms based on the NRI method (COWT) and clinical breakpoints.
| Antimicrobial | Farms Having All Isolates as Wild Type | |
|---|---|---|
| COWT | Clinical breakpoint | |
| Neomycin | 33/35 (94%) | - |
| Spectinomycin | 21/35 (60%) | - |
| Tetracycline | 9/35 (26%) | 10/35 (29%) |
| Amoxicillin/Clavulanic Acid | 30/35 (86%) | 18/35 (51%) |
| Ciprofloxacin | 32/35 (91%) | 34/35 (97%) |
| Ampicillin | 17/35 (49%) | 16/35 (46%) |
| Sulfamethoxazole-Trimethoprim | 22/35 (63%) | 26/35 (74%) |
| Chloramphenicol | 27/35 (77%) | 27/35 (77%) |
| Cefotaxime | 31/35 (86%) | 32/35 (91%) |
| Imipenem | 35/35 (100%) | 35/35 (100%) |
Figure 1Single-linkage clustering dendrograms for non-susceptibility to eight antimicrobials (A) based on the NRI COWT values in E. coli isolates from beef cattle fecal samples (n = 416); (B) based on clinical breakpoints, in E. coli isolates from beef cattle fecal samples (n = 416); (C) based on the NRI COWT values, in E. coli isolates from sheep fecal samples (n = 699); and (D) based on clinical breakpoints, in E. coli isolates from sheep fecal samples (n = 699). AMP = ampicillin, AMC = amoxicillin/clavulanic acid, C = chloramphenicol, CIP = ciprofloxacin, CTX = cefotaxime, IPM = imipenem, SXT = sulfamethoxazole-trimethoprim, TE = tetracycline.
Univariable multilevel logistic regression analysis for risk factors associated with E. coli defined as non-wild type for tetracycline.
| Factor | Unit |
| Odds Ratio (95% CI) | |
|---|---|---|---|---|
| Flock size | 1115 | 0.91 (0.46, 1.81) | 0.792 | |
| Herd size | 1115 | 0.90 (0.44, 1.82) | 0.761 | |
| Region: Wales | No | 737 | ||
| Yes | 378 | 1.62 (0.37, 7.11) | 0.523 | |
| Region: West Midlands (England) | No | 790 | ||
| Yes | 325 | 1.08 (0.23, 5.13) | 0.924 | |
| Region: Southern England | No | 823 | ||
| Yes | 242 | 0.39 (0.07, 2.25) | 0.292 | |
| Indoor samples | No | 568 | ||
| Yes | 547 | 2.90 (0.77, 10.97) | 0.116 | |
| Mixed species farm | No | 362 | ||
| Yes | 753 | 1.93 (0.41, 9.09) | 0.404 | |
| Animal species sample origin | Cattle | 416 | ||
| Sheep | 699 | 0.38 (0.11, 1.28) | 0.118 | |
| Maximum average temperature of sampling month | °C | 1115 | 0.90 (0.45, 1.79) | 0.760 |
| Minimum average temperature of sampling month | °C | 1115 | 0.79 (0.49, 1.95) | 0.939 |
| Average rainfall in sampling month | mm | 1115 | 1.23 (0.62, 2.42) | 0.556 |
| Tetracycline use | No | 159 | ||
| Yes | 956 | 22.21 (1.46, 337.52) | 0.026 | |
| Penicillin use | No | 157 | ||
| Yes | 958 | 0.62 (0.09, 4.44) | 0.635 | |
| Aminoglycoside use | No | 363 | ||
| Yes | 752 | 0.52 (0.12, 2.19) | 0.376 | |
| Macrolide use | No | 634 | ||
| Yes | 481 | 1.95 (0.48, 7.90) | 0.384 | |
| Phenicol use | No | 825 | ||
| Yes | 290 | 6.98 (1.82, 26.80) | 0.005 | |
| Sulphonamide use | No | 993 | ||
| Yes | 122 | 2.60 (0.32, 21.03) | 0.371 | |
| Soil copper concentration | mg/kg | 1115 | 1.72 (0.97–3.05) | 0.062 |
| Soil zinc concentration | mg/kg | 1115 | 0.90 (0.45, 1.78) | 0.755 |
| Soil lead concentration | mg/kg | 1115 | 1.60 (0.85, 3.00) | 0.144 |
| Soil cobalt concentration | mg/kg | 1115 | 0.65 (0.34, 1.26) | 0.206 |
Multivariable multilevel logistic regression analysis for risk factors associated with E. coli isolates being defined as non-wild type for tetracycline.
| Variable | Unit |
| Odds Ratio (95% CrI *) | |
|---|---|---|---|---|
| Tetracycline use | No | 159 | ||
| Yes | 956 | 28.22 (2.50, 520.09) | 0.014 | |
| Soil copper concentration | mg/kg | 1115 | 1.78 (1.02, 3.21) | 0.046 |
|
|
| |||
| Farm | 1.24 (0.003, 4.47) | |||
| Sample | 9.36 (4.86, 16.38) |
* CrI = credible interval.
Disk contents used to determine antimicrobial susceptibility of E. coli isolates and source of clinical breakpoints.
| Antimicrobials | Disk Content | Source |
|---|---|---|
| Neomycin | 30 μg | N/A |
| Spectinomycin | 100 μg | N/A |
| Tetracycline | 30 μg | CLSI |
| Amoxicillin/Clavulanic Acid | 20–10 µg | EUCAST |
| Ciprofloxacin | 5 µg | EUCAST |
| Ampicillin | 10 µg | EUCAST |
| Sulfamethoxazole-Trimethoprim | 23.75–1.25 µg | EUCAST |
| Chloramphenicol | 30 µg | EUCAST |
| Cefotaxime | 5 µg | EUCAST |
| Imipenem | 10 µg | EUCAST |